| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/10/2005 | WO2005020967A1 Electric drug transport preparation |
| 03/10/2005 | WO2005020966A1 Transdermal formulation comprising an opioid analgesic and an aloe composition |
| 03/10/2005 | WO2005020965A2 Skeletally targeted nanoparticles |
| 03/10/2005 | WO2005020964A1 Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| 03/10/2005 | WO2005020963A1 Process for preparing a medicament |
| 03/10/2005 | WO2005020962A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 03/10/2005 | WO2005020961A1 Pharmaceutical composition comprising anticonvulsant with taste mask coating |
| 03/10/2005 | WO2005020960A1 Preparation for rectal administration |
| 03/10/2005 | WO2005020959A2 Novel drug compositions and dosage forms of topiramate |
| 03/10/2005 | WO2005020958A2 Aerosol delivery of curcumin |
| 03/10/2005 | WO2005020957A2 Stepwise delivery of topiramate over prolonged period of time |
| 03/10/2005 | WO2005020956A2 Microparticles |
| 03/10/2005 | WO2005020954A2 Proton pump inhibitor formulations, and methods of preparing and using such formulations |
| 03/10/2005 | WO2005020953A1 Spray-dried amorphous powder with a low residual moisture and excellent storage stability |
| 03/10/2005 | WO2005020935A2 Method and composition of administering radioprotectants |
| 03/10/2005 | WO2005020933A2 Nanoparticles for drug-delivery |
| 03/10/2005 | WO2005020929A2 Sustained release dosage forms of ziprasidone |
| 03/10/2005 | WO2005020918A2 Ultrasonic concentration of drug delivery capsules |
| 03/10/2005 | WO2005020912A2 Delivery of immune response modifier compounds |
| 03/10/2005 | WO2005020906A2 Intranasal opioid compositions |
| 03/10/2005 | WO2005020901A2 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 03/10/2005 | WO2005020900A2 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 03/10/2005 | WO2005020879A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| 03/10/2005 | WO2005020876A2 Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
| 03/10/2005 | WO2005020720A1 Method for producing swelling pellets as an oral administration form for dietary fibers and swelling pellets so produced |
| 03/10/2005 | WO2005020708A1 Improved formulation for providing an enteric coating material |
| 03/10/2005 | WO2005011630A3 Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation |
| 03/10/2005 | WO2005003722A3 Nanotube structures having a surfactant bilayer inner wall coating |
| 03/10/2005 | WO2005003172A3 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| 03/10/2005 | WO2005000267A3 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat |
| 03/10/2005 | WO2004110380A3 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents |
| 03/10/2005 | WO2004108162A3 Controlled release pharmaceutical composition |
| 03/10/2005 | WO2004105731A8 Nasal formulations including a topical decongestant and a topical corticosteroid and their use in treatment of obstructive sleep apnea |
| 03/10/2005 | WO2004105689A3 Topical composition for the treatment of skin disorders and methods of using the same |
| 03/10/2005 | WO2004105687A3 Antimicrobial quaternary ammonium organosilane coatings |
| 03/10/2005 | WO2004105492A8 Aqueous compositions for disinfection and/or sterilization |
| 03/10/2005 | WO2004098562A3 Controlled release solid dosage nifedipine formulations |
| 03/10/2005 | WO2004098493A3 Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability |
| 03/10/2005 | WO2004096896A3 Microfabrication of polymer microparticles |
| 03/10/2005 | WO2004093827A3 Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| 03/10/2005 | WO2004089342A3 Oral pharmaceutical preparation comprising a proton pump antagonist and a basic exipient |
| 03/10/2005 | WO2004087105A8 Combination formulations of platinum agents and fluoropyrimidines |
| 03/10/2005 | WO2004071432A3 Method for treating hypothyroidism |
| 03/10/2005 | WO2004048411A3 Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| 03/10/2005 | WO2004030608A3 Nanoemulsion vaccines |
| 03/10/2005 | WO2003104260A3 Pharmaceutical formulation |
| 03/10/2005 | WO2003103475A3 Prevention and reduction of blood loss |
| 03/10/2005 | WO2003099681A8 Container for the generation of therapeutic microfoam |
| 03/10/2005 | US20050055014 Methods for accelerated release of material from a reservoir device |
| 03/10/2005 | US20050055013 Medication delivery device |
| 03/10/2005 | US20050054825 Osteogenic devices |
| 03/10/2005 | US20050054768 Multifunctional biocompatible hydrophilic gel and the method of gel manufacture |
| 03/10/2005 | US20050054731 Includes a biguanide hypoglycemic agent, a lipid lowering agent, a blood pressure lowering agent and, preferably, an anti-platelet agent |
| 03/10/2005 | US20050054726 Vaccine |
| 03/10/2005 | US20050054725 Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators |
| 03/10/2005 | US20050054723 Administration to the individual of a prostaglandin analogue selective for the EP2 prostanoid receptor in combination with an alpha-adrenergic agonist |
| 03/10/2005 | US20050054718 4S, 5R, 6R)-5-Acetylamino-4-azido-6-[(S)-4-nitrophenoxycarbonyloxy)-(2-oxo-[1,3]dioxolan-4R-yl)methyl]- 5,6-dihydro-4H-pyran2-carboxylic acid methylester; modified at the carboxyl or hydroxyl or amino functions; orthomyxovirus and paramyxovirus infections; a long lung residency time and high potency |
| 03/10/2005 | US20050054716 such as 7-O-methylthiomethylpaclitaxel having improved solubility, stability and oxidation resistance, for use as antitumor or anticarcinogenic agents |
| 03/10/2005 | US20050054685 Pharmaceutical composition |
| 03/10/2005 | US20050054682 Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
| 03/10/2005 | US20050054623 Transdermal supplying testosterone gel |
| 03/10/2005 | US20050054622 Administering by inhalation; antiinflammatory agents, antiallergens; skin disorders; reacting androstane compound with 2-oxofuran compound |
| 03/10/2005 | US20050054612 In situ supplying to cells; adjust hydrophobic of drugs; drug delivery |
| 03/10/2005 | US20050054611 Composition and method for use in intestinal cleansing procedures |
| 03/10/2005 | US20050054605 Partial or full A1 agonists - N6 heterocyclic 5' thio substituted adenosine derivatives |
| 03/10/2005 | US20050054602 Oligonucleotides containing activated lymphocytes; antibody therapy; antiallergens; skin disorders |
| 03/10/2005 | US20050054594 Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
| 03/10/2005 | US20050054587 Novel therapeutic indication of azithromycin for treatment of non-infective inflamatory diseases |
| 03/10/2005 | US20050054583 Composition for an antifungal agent for suppressing fungal growth in an oral cavity |
| 03/10/2005 | US20050054555 Kahalalide compounds for use in cancer therapy |
| 03/10/2005 | US20050054251 Undergarments containing active substances |
| 03/10/2005 | US20050054026 Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
| 03/10/2005 | US20050053681 Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds |
| 03/10/2005 | US20050053676 Powdered composition for use as laxative |
| 03/10/2005 | US20050053670 use of an organic lubricant and no alkali metal salts of metaphosphates in an effective amount into the birth canal of the woman during delivery |
| 03/10/2005 | US20050053669 an inorganic acid or base as core material, telmisartan, meloxicam, DT-TX 30 SE, BIBV 308 SE (terbogrel), AGEE 623 (repaglinide), gliquidone or glibenclamide or a physiologically acceptable salt, as active material layer which has pH-dependent solubility characteristics; for oral administration |
| 03/10/2005 | US20050053668 allows targeted delivery of bioactive factors to bone using nanocapsules having an amphipathic surface made of polyethylene glycol-modified phospholipid |
| 03/10/2005 | US20050053667 a hydrogel polymer; an immunogen encapsulated in said hydrogel particle; a ligand on a surface of hydrogel particle, interacts with an antigen presenting cell and providing an activation signal to antigen presenting cell |
| 03/10/2005 | US20050053666 Antibody-containing particles and compositions |
| 03/10/2005 | US20050053665 absorption of nicotine into and/or adsorption of nicotine onto cellulose of non-seed organism origin such as algae, bacteria and fungi, to stabilize nicotine; for providing a sense of smoking satisfaction without smoking |
| 03/10/2005 | US20050053664 Reduced toxicity; enhance efficiency; side effect reduction; anticarcinogenic agent; administering to a cancer patient admixture having (((1,4)-linked beta -D-mannopyranose)17-((1,6)-linked- beta -D-galactopyranose)10)12) and a chemotherapeutic agent |
| 03/10/2005 | US20050053661 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type II diabetes mellitus |
| 03/10/2005 | US20050053660 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| 03/10/2005 | US20050053659 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| 03/10/2005 | US20050053658 Extended release systems for macrolide antibiotics |
| 03/10/2005 | US20050053657 drug having a water solubility of less than one part per 30 parts water, 0.1% to 4.5% w/w of rate controlling high viscosity cellulosic ether polymers; high dose drugs with low water solubility |
| 03/10/2005 | US20050053655 microcapsules containing an antiulcer agent or antacid within a polymeric matrix formed by a hydrogel, both separated from each other by a surfactant such as lecithin |
| 03/10/2005 | US20050053654 able to disintegrate in buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 seconds, containing fexofenadine or its salt and a binder, in the form of a coated granule, and excipients such as disintegrating agent, a soluble diluent, and a lubricant |
| 03/10/2005 | US20050053653 Osmotic delivery of therapeutic compounds by solubility enhancement |
| 03/10/2005 | US20050053652 Pharmaceutical composition containing citalopram |
| 03/10/2005 | US20050053651 Stable pharmaceutical formulation |
| 03/10/2005 | US20050053650 Pills or capsules glued together to allow simultaneous delivery of multiple medication products; patient compliance |
| 03/10/2005 | US20050053649 For simultaneous delivery of multiple medication products; patient compliance; for people taking multiple drugs; dosage forms (pills, capsules) being contained within an ingestable outer container; minimal filler to keep diameter down |
| 03/10/2005 | US20050053648 For simultaneous delivery of multiple medication products; patient compliance; multiple medications are encased within separate containers which degrade within a live body; for people taking multiple drugs |
| 03/10/2005 | US20050053647 Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction |
| 03/10/2005 | US20050053646 Pressure-sensitive adhesive and patch employing the same |
| 03/10/2005 | US20050053645 Adhesive transdermal formulations of diclofenac sodium |
| 03/10/2005 | US20050053644 Prep sheets for food preparation, etc.; indents reduce slipperiness, spillage, and may prevent bacteria and/or microbe growth and/or migration through the sheet |
| 03/10/2005 | US20050053643 Externally applied medicine for baby's hernia |
| 03/10/2005 | US20050053635 Topical skin care composition containing refined peanut oil |